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Jernej Štukelj,* Mikael Agopov, Jouko Yliruusi, Clare J. Strachan, and Sami Svanbac̈k
Cite This: Anal. Chem. 2020, 92, 9730−9738 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: Salt formation is a well-established method to
increase the solubility of ionizable drug candidates. However,
possible conversion of salt to its original form of free acid or
basedisproportionationcan have a drastic effect on the
solubility and consequently the bioavailability of a drug. Therefore,
during the salt selection process, the salt dissolution behavior
should be well understood. Improved understanding could be
achieved by a method that enables simultaneous screening of small
sample amounts and detailed dissolution process analysis. Here, we
use a machine-vision-based single-particle analysis (SPA) method
to successfully determine the pH-solubility profile, intrinsic
solubility, common-ion effect, pKa, pHmax, and Ksp values of
three model compounds in a fast and low sample consumption (<1 mg) manner. Moreover, the SPA method enables, with a particle-
scale resolution, in situ observation of the disproportionation process and its immediate effect on the morphology and solubility of
dissolving species. In this study, a potentially higher energy thermodynamic solid-state form of diclofenac free acid and an intriguing
conversion to liquid verapamil free base were observed upon disproportionation of the respective salts. As such, the SPA method
offers a low sample consumption platform for fast yet elaborate characterization of the salt dissolution behavior.
Salt formation is a well-established strategy used to increasethe solubility of acidic and basic drugs.1 The initial interest
in salts dates back to studies on the dissolution rates of diverse
salt forms by Nelson in the 1950s.2 This interest has been
growing ever since, especially in recent decades, with the
solubility of new chemical entities sharply decreasing due to
production employing combinatorial chemistry and high-
throughput screening.3,4 Furthermore, potential salt form
screening for a selected drug candidate is conducted in a
high-throughput manner.5,6 A rational continuation of the
sequential process would be a high-throughput salt solubility or
dissolution screen. However, such a method that would satisfy
the high-throughput criteria and require only small sample
amounts is currently lacking. Here, we use a novel machine-
vision-based method to rapidly measure the solubility and
monitor the dissolution behavior of three model salt
compounds with minimal sample consumption.
The aqueous pH-solubility profile of an acidic or basic drug
governs whether a compound can form suitable salt candidates
as well as their resulting properties.7 A crucial value is the
pHmax, as it determines the solid phase in equilibrium with a
solution at a certain pH. At the pHmax, free acid or base and the
respective salt can coexist. For an acidic compound, a free acid
is the solid at equilibrium below the pHmax, and a salt is formed
if the pH is raised, using suitable counterions, above the
pHmax.
8,9 The opposite relationship exists for basic drugs; a salt
is formed below the pHmax, and a free base is in equilibrium
with a solution above the pHmax.
10
The equilibrium between the solid salt, acidic compound in
solution, and concentration of counterions above pHmax is
described by eq 1.1,7,9 The equilibrium between the solid salt,
basic compound in solution, and concentration of counterion
below pHmax is described by eq 2
K A Xsp = [ ][ ]
− +
(1)
K BH Xsp = [ ][ ]
+ −
(2)
where Ksp denotes the solubility product and [A
−] and [BH+]
are the concentrations of the acidic and basic compounds, salt
solubility. [X+] and [X−] are the concentrations of the
counterions. In the absence of excess counterions, the salt
solubility remains unchanged. On the other hand, excess
counterions can have a drastic impact on the solubility of the
salts, especially those with low Ksp values, a phenomenon
known as the common ion effect.11,12
For a salt of an acidic compound, if a solubility measurement
is started at a pH below the pHmax, disproportionation will
occur.13 The result will be a precipitated free acid, which will
eventually determine the solubility measured, as shown for
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phenytoin by Serajuddin et al.14 The opposite scenario unfolds
for the salt of a basic drug.15 If salt disproportionation occurs
under gastrointestinal conditions, the potential enhancement
of the dissolution rate and bioavailability can be lost.
Moreover, the disproportionation can occur as a direct
conversion into a thermodynamically stable form of a
respective free acid or base or as a more complex process,
where multiple solid-state forms appear, as observed by
Østergaard et al.16
Due to all of these parameters affecting the salt dissolution
studies, interpretation of the results can be complex but
nevertheless very important. Here, using the single-particle
analysis (SPA) method,17−20 we demonstrate a fast and
minimal sample approach to study the dissolution behavior of
salts. As the approach enables visual observation of the
dissolution process, additional insight on the particle-level
morphology changes and their immediate effect on solubility is
obtained.
■ MATERIALS AND METHODS
Materials. Naproxen free acid (NAP), naproxen sodium
(NAP−Na), and diclofenac sodium (DIC−Na) were acquired
from Sigma-Aldrich (St. Louis, MO, USA). Verapamil
hydrochloride (VER−HCl) was received from Orion Pharma
(Espoo, Finland). Diclofenac free acid (DIC) was prepared by
dissolving DIC−Na in a sufficient quantity of ultrapure water
and adding an equimolar amount of HCl while stirring. After
10 min, the precipitate was filtered and recrystallized from
ethyl acetate.
Shake-Flask (SF) Experiments. A protocol for a
miniaturized SF experiment was adapted and modified from
the work done by Bergström et al.21 DIC, DIC−Na, NAP, and
NAP−Na were, in excess of approximately 5 mg, added to
either 400 or 600 μL of the selected buffer in Eppendorf tubes.
Buffers with pH values of 2.0, 4.0, 6.0, and 8.0 were prepared
according to the United States Pharmacopeia (USP)
(Solutions/Buffer Solutions) (Table S1). For NAP, both
phosphate and borate buffers were used at pH 8.0. The
Eppendorf tubes were placed on a custom-made rotating
platform (60 rpm) at room temperature (21.5 ± 1 °C). At 48,
72, and 96 h the rotation was stopped, pHs were measured,
and samples were centrifuged at constant temperature and
21 100g for 15 min prior to sampling of the supernatant. The
supernatants were appropriately diluted and analyzed with
reverse-phase HPLC-UV. After 96 h, the solids were extracted
and analyzed using XRPD. In addition, the pHs of single
miniaturized SF experiments were measured after 24, 48, and
72 h for the USP buffers with initial pHs of 3.0, 5.0, 7.0, and
9.0 (Table S1).
HPLC Analysis. Drug concentration in the supernatants
was determined using an Agilent High Performance Liquid
Chromatography (HPLC) 1260 system (Agilent Technologies,
Germany) coupled with a Phenomenex Gemini NX-C18, 3
μm, 100 × 4.6 mm column (Phenomenex, Torrace, CA). The
temperature of the column was set to 30 °C. The mobile phase
was 0.2% H3PO4:acetonitrile (40:60, v:v for DIC and 50:50,
v:v for NAP) with a flow rate of 1 mL/min. The injection
volume was 20 μL, and detection was performed at 276 nm for
DIC and 254 nm for NAP. Standard solutions of DIC and
NAP were prepared in 0.2% H3PO4:acetonitrile (50:50, v:v)
and analyzed with HPLC-UV to construct the calibration
curve. Calibration samples were prepared in triplicate with 0.1,
1, 10, 50, 100, and 250 μg/mL (R2 > 0.999).
Differential Scanning Calorimetry (DSC). DSC meas-
urements were conducted to determine the purity and the
solid-state form of the initial samples. A DSC823e (Mettler-
Toledo, Greifensee, Switzerland) equipped with a cooling
system (Julabo FT 900, Seelbach, Germany) was used.
Nitrogen with a flow rate of 50 mL/min was used as the
purge gas.
Samples of 2−5 mg were packed into standard aluminum
crucibles (40 μL) with pierced lids. The samples were
equilibrated at 25 °C for 3 min and then linearly heated
with a heating rate of 10 °C/min. Measurements of the five
initial compounds were performed in triplicate. Thermal events
were analyzed using STARe software (Mettler-Toledo,
Greifensee, Switzerland).
X-ray Powder Diffraction (XRPD). To determine the
solid-state form of the initial samples, XRPD diffractograms
were recorded with an Aeris diffractometer (Malvern
Panalytical B.V., Almelo, The Netherlands) using Cu Kα
radiation (λ = 1.540598 Å) and a divergence slit of 0.76 mm.
Samples were placed on a low-scatter-background holder and
measured with a step size of 0.0108664° at 40 kV and 8.0 mA
from 5° to 35° (2θ). Measurements were performed in
triplicate with independent samples. Additional measurements
using XRPD were performed for the remaining solids after the
96 h miniaturized SF experiments.
SPA Measurements. The SPA measurements were carried
out as already previously described by Svanbac̈k et al. and
Štukelj et al.17,19,20 Briefly, the two main components of the
SPA method are the flow-through setup and the analysis
software. The flow-through setup enables trapping and
machine-vision tracking of drug particles under steady flow−
sink−conditions. The average measurement time is 5 min. The
captured images are then analyzed using custom-made
software, which is capable of semiautomatic particle recog-
nition and tracking of the individual particle morphology
throughout the measurement. The decrease in size, under sink
conditions, according to Noyes and Whitney, is directly
proportional to the equilibrium solubility of the compound. In
this way, the solubility data from the images is extracted.
Depending on the number of particles, the reported solubility
values are an average of up to several hundred individual
particles. For in-depth description and visuals, readers are
directed to the three original papers cited above.
■ RESULTS AND DISCUSSION
Characterization of the Solid-State Forms. The results
of the initial solid-state characterization of the five compounds
used in this study are presented in Figure 1.
The experimental XRPD diffractograms of VER−HCl, NAP,
and DIC match the predicted diffractograms from the
Cambridge Structural Database (CSD), CURHOM, COYR-
UD, and SIKLIH, respectively. NAP−Na corresponds to the
ASUBL CSD entry for the anhydrous salt form. There is no
CSD entry for the anhydrous form of DIC−Na, but the
obtained XRPD diffractogram coincides with the experimental
diffractogram of the anhydrous salt reported by A. Llinas̀ et
al.22 Moreover, the anhydrous nature of the samples is
confirmed by the absence of an endothermic dehydration
event in all of the thermograms except for NAP−Na; the
endothermic event with an onset at 55.8 ± 0.2 °C is associated
with moisture in the sample (0.34 ± 0.02%, calculated based
on the heat of evaporation of water 2400 J/g).23 The onset
temperatures of melting, seen in Figure 1b, are in good
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agreement with previously reported values of the thermody-
namically stable forms.24−29
SF pH-Solubility Profile of NAP and NAP−Na. The
solubility profiles of NAP and the respective sodium salt
(Figure 2a) were obtained with the miniaturized SF method.
Importantly, the pH of the buffers was not adjusted during the
experiment. Consequently, a pH shift occurred upon
dissolution of the solid material, and the data was plotted
accordingly. The pH shift was most pronounced, upon
addition of NAP−Na, for the buffer with an initial pH of
2.0. This can be explained by the buffer capacity originating
solely from the low pH (Supporting Information S2).
When the starting material was NAP, the same form
remained throughout the experiment (Figure 3). In contrast,
when the starting material was NAP−Na, a solid-state change
occurred. At the initial pHs of 2.0, 4.0, and 6.0, the salt
converted into a free acid (Figure 3). At pH 8.0, both in borate
and in phosphate buffer, the anhydrous salt converted into its
hydrate form. On the basis of the solid-state landscape of
NAP−Na hydrates,30 one could assume that formation of
NAP−Na tetrahydrate took place. However, XRPD diffracto-
grams of NAP−Na at pH 8.0 (Figure 3) did not exactly match
any of the diffractograms of NAP−Na hydrates (monohydrate,
two dihydrate polymorphs, and tetrahydrate) reported by
Raijada et al.30 Thus, it is most likely that multiple hydrate
forms were present or possibly an unreported form.
Intriguingly, the samples with an initial pH of 6.0, which
shifted to pH 7.7 during the experiment, and those with an
initial pH of 8.0 had similar solubility values despite being in
different solid-state forms at equilibrium (Figures 2a and 3).
This indicates the proximity of a pHmax; below the pHmax, the
solid in equilibrium is free acid, and above the pHmax, the solid
in equilibrium is salt.
SPA pH-Solubility Profile of NAP. In Figure 2a, it can be
seen that the SPA solubility values for NAP correlate well with
the SF values and also with the theoretically predicted values
based on the Henderson−Hasselbalch equation.9,31 However,
a deviation can be seen for the three values at pH 8 and above.
The values deviate because they are plotted against the pH of
the initial buffer and not against the pH on the solid−liquid
interface at which dissolution actually takes place, i.e., the
microenvironmental pH.32 According to the diffusion layer
theory, a layer of saturated solution surrounds a dissolving
particle.33 Therefore, one can assume that the micro-
environmental pH shift in the layer of saturated solution
around the particle is the same as the pH shift of the saturated
solution at the end of the SF experiment. When the SPA
solubility values are plotted against the pH values measured at
Figure 1. XRPD diffractograms (a) and DSC thermograms (b) of the
studied compounds. Onsets of melting temperature are listed next to
the respective melting peaks. Figure 2. (a) pH-solubility profiles of NAP and NAP−Na obtained
with the SPA and the SF methods. Two values for NAP−Na SPA
solubility at pH 6.0 correspond to the solubilities measured before
(higher) and after (lower) disproportionation. Two values for NAP
SPA solubility at pH 8.0 correspond to solubilities measured in borate
(lower) and phosphate (higher) USP buffer. Dashed line represents
the theoretical solubility profile based on the Henderson−Hasselbalch
equation. Dotted lines are fitted linearly (i) to the SPA NAP−Na
solubility values to estimate the pHmax and (ii) to the SPA NAP
solubility values to estimate the pKa. (b) pH-solubility profile of NAP
obtained with the SPA method and corrected for the surface pH
change due to the self-buffering effect. Dashed line represents the
theoretical solubility profile based on the Henderson−Hasselbalch
equation. Dotted lines are fitted linearly to the SPA pH-corrected
values to estimate the pKa and also horizontally to the SF values of
NAP−Na above pH 8 to estimate the pHmax. S0 is the intrinsic
solubility.
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the end of the respective SF experiments, a better correlation is
achieved (Figure 2b). The effect of microenvironmental pH on
the solubility determined with the SPA method is best seen for
the two solubility values of NAP at pH 8; at this pH, borate
USP buffer has a buffer capacity approximately 2-fold lower
than that of phosphate USP buffer (Table S1 and Figure S1).
Thus, the measured solubility in borate buffer was lower as the
microenvironmental pH shift was more pronounced. However,
when both solubility values are plotted against the pH at the
end of the respective SF experiments, they follow the
theoretically predicted pH-solubility profile. The observed
pH shifts are also supported by calculations presented in the
Supporting Information S2 and Table S1. Nonetheless, when
estimating the pKa values based on the two pH profiles, very
similar values of 4.15 (Figure 2a) and 4.18 (Figure 2b) are
obtained (Table 1). This is because the pH shift is less
pronounced at pH values up to 7.0, which were used for
estimating the pKa in Figure 2a. For comparison, previously
reported pKa and intrinsic solubility values for NAP are listed
in Table 1.
SPA pH-Solubility Profile of NAP−Na. In the SPA pH-
solubility profile of NAP−Na (Figure 2a), two regions can be
identified: the flat region above pH 6.0 where the actual
solubility of the salt is measured and the region below pH 6.0
where, after disproportionation occurs, the solubility of NAP is
measured. The process of disproportionation as observed
during the SPA measurement is shown in Figure 4; at pH 3.0,
instant dissolution of the initial particles is followed by the
appearance of needle-shaped particles, which continue to grow
for a couple of seconds and then start to dissolve. Formation of
needle-shaped particles was confirmed with SEM (Supporting
Information S2 and Figure S2). The solubility measured upon
disproportionation of NAP−Na is in agreement with the
solubility of NAP. Therefore, one can conclude that
disproportionation into the thermodynamically stable solid-
state form took place. However, in the study performed by
Østergaard et al., formation of multiple solid-state forms upon
disproportionation was observed.16 Upon monitoring the
dissolution of a compact of NAP−Na in 0.1 M HCl (pH
1.0) inside a dissolution cell with UV-imaging and Raman
spectroscopy, they observed that the NAP−Na rapidly
converted into three different intermediate solid-state forms
followed by the slower appearance (20 min) of the
thermodynamically stable NAP. It must be noted that in one
of the experiments at pH 2.0 we observed a higher solubility
value of 1.3 ± 0.6 mM (−2.9 in log units) upon
disproportionation into smaller grain-like particles (Figure
S3). However, upon multiple repetitions of the experiment,
disproportionation into needle-shaped particles predominated,
and therefore data from these latter experiments are plotted in
Figure 2a. This behavior underscores the complex process of
NAP−Na disproportionation as described by Østergaard et
al.16
In general, the pH-solubility profile of an acidic compound is
described with two curves: one where the free acid is the solid
phase at equilibrium, and the second where the salt is the solid
phase at equilibrium.1 At the thermodynamic equilibrium, in
certain conditions, the most stable solid-state forms of either
free acid or salt (or both at pHmax) are present. Therefore, it is
vital to consider the solid-state form of the dissolving solid
when interpreting the SPA pH-solubility profile. NAP−Na
disproportionated into the thermodynamically stable form of
NAP in the pH range from 2 to 6. Disproportionation was also
Figure 3. XRPD diffractograms of the starting materials (NAP and
NAP−Na) and samples at the end of the SF experiments started with
NAP (red) and NAP−Na (blue). On the right side, pH shifts that
occurred during the respective SF measurement are listed. (*)
Phosphate USP buffer.
Table 1. Intrinsic Solubility (S0), pKa, and pHmax Values
Obtained in This Study Compared with Those in the
Literature (lit.)
naproxen diclofenac
pKa SPA 4.15 4.26
pKa lit. 4.18
a 4.08b
S0 SPA (μg/mL) 25 ± 13 0.6 ± 0.3
S0 lit. (μg/mL) 16,
a 14c 1.0 ± 0.7,a 0.8 ± 0.2,b 0.9 ±0.1d
naproxen sodium diclofenac sodium
pHmax′ SPA 7.97 7.35
pHmax lit. ∼8c ∼8a,e
aReference 38. bReference 22. cReference 9. dReference 39.
eReference 34.
Figure 4. In situ disproportionation as observed during the SPA
experiments of NAP−Na at pH 3.0. Initial dissolution followed by
appearance and growth of needle-shaped particles.
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confirmed with FT-IR spectral analysis of the solid-state
change in the SPA experiment conducted at pH 2 and 3,
Supporting Information S3 and Figure S4. Moreover, the
solubilities closely matched the SF and SPA values of NAP.
However, for the salt region, above pH 6, such an absolute
conclusion cannot be made. The SPA measurement was
conducted with the anhydrous NAP−Na. This explains the 11-
fold higher solubility when compared to the SF values for the
in situ formed NAP−Na hydrate (Figures 2a and 3). Thus, the
intersect of the two regions in Figure 2a results in an apparent
pHmax ́ value of 7.97 (Table 1). On the other hand, the pHmax
can also be determined by linearly extrapolating the pH-
corrected SPA values of NAP to the SF-determined solubility
of NAP−Na as shown in Figure 2b. In this case, the value of
7.30 is obtained. On the basis of the solubility of the salt above
pHmax′ measured with the SPA, an apparent solubility product
of the saltKsp′ can be calculated using eq 1, where [A−] is the
salt solubility of NAP and [X+] is the counterion (Na+)
concentration.1 In the absence of excess counterion, [A−]
equals [X+] and a Ksp′ of 53.4 mol2/L2 is obtained for NAP−
Na.
SF pH-Solubility Profile of DIC and DIC−Na. The
solubility profiles of DIC and DIC−Na obtained with the
miniaturized SF method are shown in Figure 5a. The pH of the
buffers was not adjusted during the experiment. Consequently,
a pH shift occurred upon dissolution of the solid material, and
the data was plotted accordingly. When the starting material
was DIC, it remained in the same form throughout the
experiment (Figure 6). On the contrary, when the starting
material was DIC−Na, a solid-state change occurred. At initial
pH values of 2.0 and 4.0 the salt converted into a free acid
form as shown in Figure 6. At initial pH values of 6.0 and 8.0,
the anhydrous salt converted into its hydrate form. Previous
studies suggest formation of DIC−Na tetrahydrate in an
aqueous environment.35,36,34,35 However, there is currently no
CCD entry for the DIC−Na tetrahydrate, so the theoretical
diffractogram for comparison could not be plotted. Never-
theless, the XRPD diffractogram obtained in this study (key
peak positions 13.4, 17.9, 22.5, and 36.4) coincided closely
with the XRPD pattern of DIC−Na tetrahydrate (DSH1)
reported by M. Bartolomei et al.36 Intriguingly, the sample
with an initial pH of 2.0, which shifted to 7.9 during the
experiment, had a similar solubility as the two samples with
initial pH values of 6.0 and 8.0, despite being in different solid-
state forms at equilibrium (Figures 5a and 6). This indicates
the proximity of the pHmax; below the pHmax, the solid in
equilibrium is free acid, and above the pHmax, the solid in
equilibrium is a salt.1
SPA pH-Solubility Profile of DIC. The SPA solubility
values for DIC correlate well with the SF values and also with
the theoretically predicted values based on the Henderson−
Hasselbalch equation (Figure 5a).9,31 However, an increasing
deviation from the theoretical line can be seen with the
increasing pH. Similarly as with the NAP, the values deviate
because they are plotted against the pH of the initial buffer and
not against the pH on the liquid−solid interface at which
dissolution actually takes place. If the SPA solubility values are
corrected with the pH values measured at the end of the
respective SF experiments, a shift to the left can be observed
(Figure 5b). Observed pH shifts are also supported by
calculations presented in Supporting Information S2 and Table
S1. When estimating the pKa values based on the two pH-
solubility profiles, the values of 4.26 (Figure 6a) and 4.61
(Figure 6b) were obtained. For comparison, previously
reported pKa and intrinsic solubility values for DIC are listed
in Table 1.
Figure 5. (a) pH-solubility profile of DIC and DIC−Na obtained
with the SPA and SF methods. Dashed line represents the theoretical
solubility profile based on the Henderson−Hasselbalch equation.
Dotted lines are fitted linearly (i) to the SPA DIC−Na solubility
values to estimate the pHmax and (ii) to the SPA DIC solubility values
to estimate the pKa. (b) pH-solubility profile of DIC obtained with
the SPA method corrected for the surface pH change due to the self-
buffering effect. Dashed line represents the theoretical solubility
profile based on the Henderson−Hasselbalch equation. Dotted lines
are fitted linearly to the SPA pH-corrected values to estimate the pKa
and also horizontally to the two SF values of DIC−Na that converted
into hydrate form to estimate the pHmax. S0 is the intrinsic solubility.
Figure 6. XRPD diffractograms of the starting material (DIC and
DIC−Na). XRPD diffractograms at the end of the SF experiments
started with the DIC (red) and the DIC−Na (blue). On the right, pH
shifts that occurred during the respective SF measurements are listed.
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Despite having similar pKa values, the microenvironmental
pH shift during the dissolution of DIC was less pronounced
than the microenvironmental pH shift during the dissolution of
NAP. This is the consequence of the lower intrinsic solubility
of DIC as described by K. Mooney et al.; the self-buffering
capacity increases with increasing solubility of the unionized
species of the drug.37
SPA pH-Solubility Profile of DIC−Na. The SPA pH-
solubility profile of DIC−Na (Figure 5a) resembles the
elevated pH-solubility profile of DIC. Again, two regions can
be identified: the flat region roughly above pH 8 where the
solubility of the salt is measured and the region below pH 8. In
the region below pH 8, the disproportionation was observed
during the SPA experiments up to pH 5.0 (Figure 7). For the
measurements conducted at pH 6.0 and 7.0 the disproportio-
nation most likely also occurred as indicated by the shape of
the pH-solubility profile, though it was not visually detected
due to its subtle nature and the fast dissolution of particles.
Intriguingly, unlike with NAP−Na, DIC−Na exhibited
higher solubility upon disproportionation when compared to
the respective solubilities of DIC. Confirmation of dispro-
portionation was achieved by measuring the FT-IR spectrum
upon observation of the solid-state change in the SPA
experiments conducted at pH 2 and 3, Supporting Information
S3 and Figure S5. This kind of behavior for DIC−Na was, at
least to our knowledge, not yet reported in the literature.
Higher solubility could be the result of in situ formation of a
metastable polymorph or amorphous solid of DIC. Thus, if
measured for a sufficient period of time, as in a SF experiment,
the solubility would decrease to that of a thermodynamically
stable form of DIC.
For the salt region, as with the NAP−Na, the SPA
measurement was started with anhydrous DIC−Na, which
resulted in higher solubility values when compared to the
respective SF values. As shown by the XRPD of the remaining
SF solids in Figure 6 and based on the literature data discussed
above, DIC−Na anhydrate converged during the SF experi-
ment started at pH 6 and 8 into its tetrahydrate form.36 There
are several more hydrate forms of DIC−Na reported in the
literature.22,36,40 On the basis of these reports and on the
results obtained in this study, the higher solubility of DIC−Na
in the salt region measured with the SPA when compared to
the SF values can be explained in two ways. The actual
solubility of the anhydrous form was measured or, less likely, in
the time span of the SPA experiment, the conversion to
another thermodynamically unstable hydrate form occurred.
Thus, as thermodynamically stable forms of free acid and
hydrate salt were not measured in the SPA experiments, when
starting with DIC−Na, the intersect of the two regions, Figure
5a, results in an apparent pHmax′ value of 7.35 (Table 1). On
the other hand, the actual pHmax can also be determined by
linearly extrapolating the pH-corrected SPA values of DIC to
the SF-determined solubility of DIC−Na as shown in Figure
5b. In this case, the value of 7.98 is obtained. On the basis of
the solubility of the salt above pHmax′ measured with the SPA,
an apparent solubility product of the salt Ksp′ was calculated
using eq 1, and a value of 0.50 mol2/L2 was obtained for DIC−
Na.
SPA pH-Solubility Profile of VER−HCl. A pH-solubility
profile of VER−HCl as obtained with the SPA method (Figure
8) is in good agreement with the data reported by
Surakitbanham et al.41 A SF experiment for VER−HCl was
not conducted in this study due to the liquid solid state of
verapamil free base (VER) at room temperature. This might
also be the reason for the lack of solid-state characterization of
the precipitate in the SF experiments conducted by
Surakitbanham et al.41 Nevertheless, the liquid state of the
VER resulted in intriguing phenomena observed during the
SPA experiments.
In Figure 9a, the dissolution during the SPA experiment of
VER−HCl at pH 7 can be seen. During the dissolution, the
particles seem to behave as they would suddenly swell and then
burst in the process. This is most likely the result of salt
disproportionation forming a liquid VER. The solubility was
measured before bursting of the individual particles occurred.
Figure 7. In situ disproportionation as observed during the SPA
experiments of DIC−Na at pH 2.0. Disintegration/dissolution of
initial particles resulted in formation of a supersaturated area followed
by the appearance of particles with different morphology.
Figure 8. pH-solubility profile of VER−HCl as obtained with the SPA
method and the solubility of dexverapamil as reported by
Surakitbanham et al.41 Dashed line represents the theoretical
solubility profile based on the Henderson−Hasselbalch equation,
pKa = 8.9, and S0 = 6.6 × 10−5 mol/L.
41
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However, the disproportionation on the particle surface
probably occurred prior to bursting, resulting in formation of
a liquid free base layer surrounding the particle and hence the
good agreement with the SF result obtained by Surakitbanham
et al.41
In Figure 9b, the dissolution, during the SPA experiment, of
VER−HCl at pH 9 can be seen. In this case, the particles
behave differently when compared to their dissolution at pH 7.
The process of solid-state change, which can be visually
observed, is slower, taking several minutes compared to several
seconds (Figure 9a and 9b). Particles merge forming bigger
and rounder entities inside of which eventually a void,
resembling a bubble, is formed. This behavior is consistent
with formation of the liquid free base. Solubility values were
extracted from roughly the first 50 s of the image data, before
extensive changes were observed. Again, the solubility value
matches that reported by Surakitbanham et al.,41 indicating
dissolution limited by the VER.
At pH 6 in Figure 8, a positive deviation from the theoretical
curve can be seen. The theoretical curve was constructed based
on the Henderson−Hasselbalch equation with values of pKa =
8.9 and S0 = 6.6 × 10
−5 mol/L adopted from Surakitbanham et
al.41 The researchers in that study explain the positive
deviation from the theoretical curve with formation of VER
dimers. The fact that a positive deviation is also seen in the
SPA experiments indicates the rapid formation of dimers in the
unstirred layer surrounding the particles.
In the region below pH 5, no visual solid-state change was
observed. Thus, one can assume the solubility of the
hydrochloride salt was measured and that the pHmax of the
respective salt is between pH 5 and pH 6. The solubility
measured in this region was lower than that at pH 6 due to a
substantial common-ion effect as also seen with other basic
drugs.11,42 The solubility at pH 2 was then significantly higher,
which is inconsistent with the common-ion effect, but most
likely occurred due to the pH-limited buffer capacity of the
HCl USP buffer used at pH 2 when compared to the phthalate
USP buffers used at pH 3, 4, and 5 (Supporting Information S2
and Figure S1).
■ CONCLUSIONS
In this study, we demonstrated the use of the SPA method for
understanding the dissolution behavior of salt compounds.
NAP−Na, DIC−Na, and VER−HCl were used as model salt
compounds. In total, less than 1 mg of each compound was
used for all of the SPA measurements. In contrast, the
corresponding analyses conducted with miniaturized SF
experiments require from 100 mg up to 10 g of compound,
depending on the solubility. As the amount of sample needed
for the SPA experiment is so small, possible total dissolution
during the course of the measurement can prevent subsequent
offline solid-state characterization. However, this study
demonstrates that visually detectable solid-state changes may
still provide crucial information for the interpretation of the
measured solubility.
On the basis of the obtained pH-solubility profiles, intrinsic
solubility, pKa, pHmax, and Ksp values were determined.
Moreover, a transient higher solubility of DIC−Na and
intriguing behavior of VER−HCl upon disproportionation
were observed. The importance of the sample solid-state and
the possible microenvironmental pH shift was addressed in the
context of the SPA measurements. Finally, the study has
demonstrated that the SPA method is a powerful tool as it
enables visual in situ observation of the salt disproportionation
process on the particle level and its direct impact on the
solubility of a potential salt candidate. As such, the method has
much potential as a low sample consumption platform
enabling elaborate characterization of the salt dissolution
behavior.
Figure 9. Change of sample morphologyin situ disproportiona-
tionduring the SPA experiments. (a) VER−HCl at pH 7.0. During
dissolution, particles suddenly swell and then burst due to
disproportionation into the liquid VER. (b) VER−HCl at pH 9.0.
Throughout the dissolution process, particles merge into bigger
rounded entities. Inside of these entities a void resembling a bubble is
formed.
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